| 1.44 0.18 (14.29%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.83 |
1-year : | 2.14 |
| Resists | First : | 1.57 |
Second : | 1.83 |
| Pivot price | 1.3 |
|||
| Supports | First : | 1.29 |
Second : | 1.12 |
| MAs | MA(5) : | 1.29 |
MA(20) : | 1.27 |
| MA(100) : | 1.35  |
MA(250) : | 1.88 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 36.5 |
D(3) : | 29.4 |
| RSI | RSI(14): 62 |
|||
| 52-week | High : | 4.4 | Low : | 1.03 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ RNTX ] has closed below upper band by 5.3%. Bollinger Bands are 17.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.46 - 1.47 | 1.47 - 1.47 |
| Low: | 1.27 - 1.27 | 1.27 - 1.28 |
| Close: | 1.43 - 1.44 | 1.44 - 1.45 |
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
Fri, 24 Oct 2025
Rein Therapeutics secures third $1 million advance from Yorkville under financing deal - Investing.com
Thu, 09 Oct 2025
Rein Therapeutics Receives EMA Approval for Phase 2 IPF Trial - TradingView
Thu, 09 Oct 2025
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis - Yahoo Finance
Tue, 30 Sep 2025
Rein Therapeutics (RNTX) Price Target Increased by 42.86% to 10.20 - Nasdaq
Wed, 30 Jul 2025
Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing - Yahoo Finance
Wed, 30 Jul 2025
Rein Therapeutics Lands $21M Strategic Financing to Advance Breakthrough IPF Drug Trial - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 24 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 33.8 (%) |
| Shares Short | 16 (K) |
| Shares Short P.Month | 27 (K) |
| EPS | -2.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.12 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -18.3 % |
| Return on Equity (ttm) | -79.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -21 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.5 |
| PEG Ratio | 0 |
| Price to Book value | 11.07 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|